Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Beckman Coulter Obtains CE Mark for VERIS MDx System

Published: Monday, May 12, 2014
Last Updated: Monday, May 12, 2014
Bookmark and Share
Beckman Coulter Diagnostics has obtained CE Mark for the VERIS MDx System* and VERIS human Cytomegalovirus (CMV) assay*.

Attaining CE Mark on the VERIS MDx System and the VERIS CMV assay are key milestones in the expansion of Beckman Coulter’s presence in molecular diagnostics.

“After extensive research and development, Beckman Coulter has applied its expertise in diagnostics with our in-depth knowledge of workflow to bring molecular diagnostics to the clinical laboratory,” said Richard Creager, senior vice president, Molecular Diagnostics Business Unit, and chief scientific officer at Beckman Coulter Diagnostics. “We have spent tremendous effort on understanding the needs of molecular laboratory professionals to develop a system that simplifies molecular diagnostic testing, while delivering the results that patients and clinicians need.”

The VERIS MDx System is a fully automated, random access molecular diagnostics system for the quantitative and qualitative analysis of molecular targets from clinical patient specimens.  The VERIS system integrates key steps in molecular diagnostics to streamline workflow and system management, while also processing critical STAT samples and ensuring prompt delivery of results. By providing continuous access, one-step loading and individual test reporting, VERIS helps medical laboratory professionals advance and optimize the molecular diagnostics lab, by providing the control and freedom to give the right answer at the right time — for patients and physicians.

The VERIS CMV assay is a Polymerase Chain Reaction (PCR) assay designed for the quantitative determination of CMV deoxyribonucleic acid (DNA) from human plasma. When used in conjunction with clinical presentation and other laboratory findings, the VERIS CMV assay aids in monitoring CMV viral load. 

Beckman Coulter is committed to the ongoing development of assays to expand the VERIS infectious disease portfolio and plans to submit for CE Mark on assays for Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) in 2014.

*Not for sale or distribution in the U.S.; not available in all markets.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Beckman Coulter Diagnostics and Seegene Supply Agreement
Supply agreement announced for multiplex reagents for VERIS molecular diagnostics system.
Monday, November 17, 2014
Beckman Coulter, Inc. Obtains CLIA Certificate, Licensure for Clinical Sequencing
Certification paves the way for genetic testing of patient samples by Beckman Coulter Genomics.
Wednesday, May 09, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Linkage Biosciences Awarded NHS Contract
Comapny announces that it has been awarded a four-year contract by NHS Blood and Transplant (NHSBT) in the UK for implementation of the LinkSeq™ Real-Time PCR HLA typing product.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Frankfurter Fraud: Finding Out What’s In Your Hot Dog
Scientists have developed a technique to test the meat content of Frankfurters.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos